Bosutinib versus placebo for autosomal dominant polycystic kidney disease
Journal of the American Society of Nephrology Aug 30, 2017
Tesar V, et al. – This study gauged the efficacy of bosutinib versus placebo for autosomal dominant polycystic kidney disease (ADPKD). According to results, bosutinib at 200 mg/d reduced kidney growth in patients with ADPKD than placebo. This study did not find new toxicities.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries